GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (OTCPK:BMXMF) » Definitions » Other Long Term Assets

BMXMF (BioMerieux) Other Long Term Assets : $307 Mil (As of Jun. 2024)


View and export this data going back to 2009. Start your Free Trial

What is BioMerieux Other Long Term Assets?

BioMerieux's other long-term assets for the quarter that ended in Jun. 2024 was $307 Mil.

BioMerieux's quarterly other long-term assets increased from Jun. 2023 ($173 Mil) to Dec. 2023 ($349 Mil) but then stayed the same from Dec. 2023 ($349 Mil) to Jun. 2024 ($307 Mil).

BioMerieux's annual other long-term assets increased from Dec. 2021 ($120 Mil) to Dec. 2022 ($172 Mil) and increased from Dec. 2022 ($172 Mil) to Dec. 2023 ($349 Mil).


BioMerieux Other Long Term Assets Historical Data

The historical data trend for BioMerieux's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMerieux Other Long Term Assets Chart

BioMerieux Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 174.56 167.03 120.34 172.25 349.29

BioMerieux Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.30 172.25 172.70 349.29 307.32

BioMerieux Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.


BioMerieux Business Description

Traded in Other Exchanges
Address
Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (34% of 2023 sales), microbiology (39%), immunoassays (10%), and industrial applications (about 17%). The Amercas account for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (31%), and Asia-Pacific (16%). BioMérieux is headquartered in Marcy-l'Etoile, France.

BioMerieux Headlines

From GuruFocus

Full Year 2020 Biomerieux SA Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q1 2022 Biomerieux SA Business Results Call Transcript

By GuruFocus Research 02-12-2024

Half Year 2024 Biomerieux SA Earnings Call Transcript

By GuruFocus Research 09-06-2024

Q1 2021 Biomerieux SA Business Review Transcript

By GuruFocus Research 02-12-2024

Half Year 2022 Biomerieux SA Earnings Call Transcript

By GuruFocus Research 02-12-2024

Q3 2023 Biomerieux SA Corporate Sales Call Transcript

By GuruFocus Research 02-12-2024

bioM�rieux Introduces GENE-UP� ENVIROPRO�

By PRNewswire PRNewswire 02-02-2023

Q1 2023 Biomerieux SA Corporate Sales Call Transcript

By GuruFocus Research 02-12-2024

Q3 2020 Biomerieux SA Business Review Call Transcript

By GuruFocus Research 02-12-2024

Q3 2021 Biomerieux SA Business Review Call Transcript

By GuruFocus Research 02-12-2024